The EXXCHANGE’s Post

What are the best approaches for startups to build meaningful connections with investors and maximize warm introductions? In this clip, the panelists discuss the importance of warm introductions and relationship-building regarding fundraising. Panelists stressed that warm intros, facilitated by trusted advisors or board members, are far more effective than cold emails or lengthy pitches. They advised keeping email outreach concise—highlighting key details like fundraising goals and lead investors—while avoiding unnecessary complexity. Leveraging tools like LinkedIn to identify and tap into mutual connections can further open doors. In a tight-knit community like Medtech, the key takeaway is clear: fostering personal relationships and tailoring your approach is essential for successful investor engagement. To hear more from this incredible group of panelists tune into the full LSI Europe ‘24 panel "Light at the End of the Tunnel in Medtech Financing”, on our website and YouTube channel featuring: • Nick Pachuda (Moderator) — Precision Life Science Partners • Martin Omid A. — Anthro Ventures • Anita Watkins — Rex Health Ventures • Sean Morris — Cultivation Capital • Eman Namati — SpectraWAVE, Inc. - Want to attend our next event? LSI USA ‘25 will be held March 17th-21st in Dana Point, California. Apply today on our website.

If you have an idea for a patent visit us at menloparkpatents.com to see how our reasonably priced fixed fee services by USPTO licensed team members can help you. If you need a trademark visit wizardip.com to see how our US Licensed attorneys can help you with our fixed fee services. #patent #provisionalpatent #invention #innovation

Last week at the London Institute for Healthcare Engineering I was fortunate to host a panel with Kelly Klifa, CEO and Co-founder of Ally Health, and Ruth Coleman, Investment Manager at Mercia Ventures for their #MedTech founders focused on sustainable and strategic growth for #venture backed businesses. 📚 Key Takeaways from the Panel: 1️⃣ Strategic Business Support: Technical founders can progress far without direct commercial expertise when they have knowledgeable advisors or board members who offer essential commercial guidance. 2️⃣ Building a Strong Board: A robust board is crucial—not only as a vehicle for capital acquisition but as a pivotal element in scaling teams and ensuring strategic alignment. 3️⃣ Cap Table Strategy: Establishing a clear, sustainable cap table early on is fundamental for supporting long-term growth and transparent financial planning - especially with co-founding teams Thank you Antoinette C. Valentina Vitiello Nicolas Huber for having us at the London Institute for Healthcare Engineering

Join our Capital Readiness Program or tell your Founders. This program will transform your/their business.

🔬 Unlock New Horizons in Biotech Funding Imagine your biotech innovations reaching the eyes of investors who can truly appreciate and support your vision. Strategic outreach techniques, such as look-alike acquisition funnels, are the key to finding and engaging with these perfect matches. These advanced tools transform casual interest into committed backing. Don’t miss out on the funding opportunities your breakthroughs deserve. Ready to explore? Let’s connect and seize these opportunities! #BiotechGrowth #StrategicFunding #InnovationPotential

After a productive networking break in the Great Room Foyer, we now have the “Medtech by the Numbers” Panel Session, moderated by Jennifer McMahon, Partner at Seroba.: • Inga D. Deakin, Principal, Molten Ventures • Megan MacDonagh, Vice President, SV Health Investors • Anne Portwich, Partner, EQT Life Sciences  • Sylvain Sachot, Partner, Asabys Partners 2023 life science investment went down across the board, in biotech and medtech equally, but in diagnostics and healthtech to a greater degree. A panel of European VCs discusses what’s in store for 2024. The number of up-rounds is down, which is a negative for VC firms supporting early-stage companies. The situation needs to change in order to reward early investment, the lifeblood of medtech innovation. We are seeing a lot of structured deals, option deals with many milestones. It does look good when a strategic is interested in a company, and it provides a path for exit. But it is a two-sided sword.   Remain informed on new articles, conference updates and more with our helpful medtech community newsletter. Subscribe here: https://bit.ly/42KHJKI

Got a groundbreaking scientific idea? When it comes to pitching to non-scientific investors, it's not just about the science—it's about connecting, simplifying, and showing them the potential. Here's Ruby Leaf Media's guide on how to bridge the gap and make an impact. Take our MedTech Matchmaker Quiz today and gain valuable insights for partnership success: https://lnkd.in/gGNzEqCG #InnovateWithPurpose #DiversityInTech #ScienceStartups #NextGenTechPartners

As a biotech CEO gearing up for an IPO, you know science is your foundation—but perception drives investment. Your messaging matters as much as your science. Investors want clarity, confidence, and a narrative they can champion. This is where your branding needs to shine. At MSC, we specialize in preparing biotech companies for the IPO spotlight. Here’s how we can help you: Distill Complexity: We turn dense mechanisms of action into compelling, investor-friendly visuals and messaging. Craft Your Message: MSC develops messaging that speaks to science, market potential, and impact. Build Trust: We make sure to align your mission with investor and partner values, creating a brand that feels as credible as your research. You’ve done the hard work in the lab. Let us ensure the world sees your vision with the clarity and excitement it deserves. MSC Makes Science Click

Over the past 6+ months I met with 50 board members of early stage biotechs (seed stage and early series stage) to discuss their experiences on boards in an effort to better understand cash compensation/equity, time commitment, board composition, meeting mechanics/best practices, motivation, etc. In addition, we also reviewed fifty S-1 filings 📃 from recent IPOs to gather pre-IPO data on board composition and compensation. Here are some common suggestions and observations gleaned from our conversations👇 ✔ No surprises at the board meeting. ✔Many board chairs have 1:1 conversations with each board member prior to meetings. ✔Send materials out to board members at least 1 week in advance. ✔If delivering science/technical presentations, you need to save time to discuss and make decisions. ✔May be beneficial to have these presentations in a separate session prior instead of trying to cram it into a board meeting. ✔Create opportunities for the board to meet and get to know key leaders on your team. ✔Board agreements were often (not always) used and generally include confidentiality agreements, and compensation/equity details. Some reported agreements included term limits, potential conflict of interest disclosures, an board roles and expectations. ✔There are many board candidates who don’t expect cash compensation for seed stage/early series stage biotech boards. They all expect equity, but motivation isn’t typically financially driven. ✔Board motivation includes desire to give back, opportunity to stay active in life sciences after retirement, and an opportunity to see the business from a different angle. **If you are interested in a copy of our report, please shoot me a message. #boards #benchmarks #biotech

🚀 Great to see Blaze.tech featured in the Black Opal Ventures inaugural impact report! This report provides a great snapshot of the impact of their portfolio companies on driving better health outcomes through innovation.👇